Free Trial
NASDAQ:ASRT

Assertio (ASRT) Stock Price, News & Analysis

Assertio logo
$0.65 -0.01 (-2.19%)
Closing price 04:00 PM Eastern
Extended Trading
$0.65 0.00 (-0.61%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Assertio Stock (NASDAQ:ASRT)

Key Stats

Today's Range
$0.65
$0.67
50-Day Range
$0.53
$0.71
52-Week Range
$0.51
$1.80
Volume
177,434 shs
Average Volume
664,652 shs
Market Capitalization
$62.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75
Consensus Rating
Buy

Company Overview

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Assertio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

ASRT MarketRank™: 

Assertio scored higher than 28% of companies evaluated by MarketBeat, and ranked 685th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Assertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Assertio has only been the subject of 2 research reports in the past 90 days.

  • Read more about Assertio's stock forecast and price target.
  • Earnings Growth

    Earnings for Assertio are expected to grow in the coming year, from ($0.15) to $0.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Assertio is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Assertio is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Assertio has a PEG Ratio of 3.25. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Assertio has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Assertio's valuation and earnings.
  • Percentage of Shares Shorted

    6.37% of the float of Assertio has been sold short.
  • Short Interest Ratio / Days to Cover

    Assertio has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Assertio has recently increased by 9.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Assertio does not currently pay a dividend.

  • Dividend Growth

    Assertio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.37% of the float of Assertio has been sold short.
  • Short Interest Ratio / Days to Cover

    Assertio has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Assertio has recently increased by 9.68%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 1 people have searched for ASRT on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Assertio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Assertio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of Assertio is held by insiders.

  • Percentage Held by Institutions

    48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Assertio's insider trading history.
Receive ASRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter.

ASRT Stock News Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.
See More Headlines

ASRT Stock Analysis - Frequently Asked Questions

Assertio's stock was trading at $0.8711 at the start of the year. Since then, ASRT shares have decreased by 25.2% and is now trading at $0.6520.
View the best growth stocks for 2025 here
.

Assertio Holdings, Inc. (NASDAQ:ASRT) released its quarterly earnings data on Monday, May, 12th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.08. The firm earned $26.49 million during the quarter, compared to the consensus estimate of $27.52 million. Assertio had a positive trailing twelve-month return on equity of 3.79% and a negative net margin of 54.46%.
Read the conference call transcript
.

Assertio's top institutional shareholders include Nantahala Capital Management LLC (8.81%), AQR Capital Management LLC (0.66%), CM Management LLC (0.50%) and Invesco Ltd. (0.44%). Insiders that own company stock include Daniel A Peisert, Heather L Mason, William Mckee, Jeff L Vacirca, Ajay Patel, Sam Schlessinger, Paul Schwichtenberg and Brendan P O'grady.
View institutional ownership trends
.

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), Fortress Biotech (FBIO), KALA BIO (KALA), Lipocine (LPCN) and Ovid Therapeutics (OVID).

Company Calendar

Last Earnings
5/12/2025
Today
6/05/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ASRT
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.75
High Stock Price Target
$3.50
Low Stock Price Target
$1.75
Potential Upside/Downside
+321.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
3.25
Net Income
-$331.94 million
Pretax Margin
-33.94%

Debt

Sales & Book Value

Annual Sales
$119.00 million
Cash Flow
$0.58 per share
Price / Cash Flow
1.12
Book Value
$1.46 per share
Price / Book
0.45

Miscellaneous

Free Float
92,423,000
Market Cap
$62.45 million
Optionable
Optionable
Beta
0.32
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ASRT) was last updated on 6/5/2025 by MarketBeat.com Staff
From Our Partners